SCHEMBL3841758

SCHEMBL3841758

C=CCOC(c1cccc(NS(=O)(=O)c2cccc(N)c2)c1)C(N=C=O)C(=O)OCC

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.39
HTR6 P50406 2/20 0.36
ADRB2 P07550 3/20 0.36
ADRB1 P08588 3/20 0.36
ADRB3 P13945 3/20 0.36
PKM P14618 2/20 0.36
KMT2A Q03164 1/20 0.36
ALDH1A1 P00352 1/20 0.35
LMNA P02545 3/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
TP53 P04637 1/20 0.34
MAPT P10636 1/20 0.34
THRB P10828 1/20 0.34
AR P10275 1/20 0.34
HDAC3 O15379 1/20 0.34
HDAC4 P56524 1/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC7 Q8WUI4 1/20 0.34
HDAC2 Q92769 1/20 0.34
HDAC10 Q969S8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3809843 0.74 POLB (0.40) POLBHTR6ADRB2ADRB1ADRB3
SCHEMBL7150268 0.72 POLB (0.41) POLBHTR6ADRB2ADRB1ADRB3
SCHEMBL7148744 0.71 HTR6 (0.43) POLBHTR6ADRB2ADRB1ADRB3
SCHEMBL27564740 0.68 POLB (0.52) POLBHTR6ADRB2ADRB1ADRB3
SCHEMBL3834077 0.68 ALDH1A1 (0.50) POLBHTR6PKMKMT2AALDH1A1
SCHEMBL3840584 0.67 POLB (0.39) POLBHTR6PKMKMT2AALDH1A1
SCHEMBL7196506 0.66 POLB (0.47) POLBHTR6KMT2AALDH1A1LMNA
SCHEMBL7188016 0.66 POLB (0.47) POLBHTR6ADRB2ADRB1ADRB3
SCHEMBL7188012 0.66 POLB (0.47) POLBHTR6ADRB2ADRB1ADRB3
SCHEMBL3834082 0.65 HTR6 (0.51) POLBHTR6ALDH1A1CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1235595-B8 INTEGRIN-MEDIATED DRUG TARGETING BAYER SCHERING PHARMA AG (DE) 2009-10-07 EP disclosed
EP-1235595-A2 INTEGRIN-MEDIATED DRUG TARGETING Bayer Aktiengesellschaft (DE) 2002-09-04 EP disclosed
WO-2001017563-A2 INTEGRIN-MEDIATED DRUG TARGETING BAYER AKTIENGESELLSCHAFT (DE) 2001-03-15 WO disclosed